Growth factors in benign prostatic hyperplasia: Basic science implications

Current Urology Reports

Volumn 9, Issue 4, 2008, Pages 272-278

  Lucia, M Scott ^a   Lambert, James R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CYSTEINE RICH PROTEIN 61; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 9; GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CYTOKINE PRODUCTION; DISEASE COURSE; EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; MESENCHYME CELL; PATHOGENESIS; PROSTATE HYPERTROPHY; TISSUE INJURY;

FIBROBLAST GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC HYPERPLASIA; TGF-BETA SUPERFAMILY PROTEINS;

EID: 48749119744     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0048-6     Document Type: Article

References (50)

1. Berry SJ, Coffey DS, Walsh PC, et al.: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474-479.
2. Kirby RS: The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000, 56:3-6.
3. Lee C, Kozlowski JM, Grayhack JT: Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997, 31:131-138.
4. McNeal J: Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am 1990, 17:477-486.
5. Bierhoff E, Walljasper U, Hofmann D, et al.: Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate 1997, 31:234-240.
6. Giri D, Ropiquet F, Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999, 5:1063-1071.
7. Ropiquet F, Giri D, Lamb DJ, et al.: FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999, 162:595-599.
8. Nishi N, Matuo Y, Muguruma Y, et al.: A human prostatic growth factor (hPGF): partial purification and characterization. Biochem Biophys Res Commun 1985, 132:1103-1109.
9. Ittman M, Mansukhani A: Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997, 157:351-356.
10. Boget S, Cereser C, Parvaz P, et al.: Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not. Eur J Endocrinol 2001, 145:303-310.
11. Muller WJ, Lee FS, Dickson C, et al.: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 1990, 9:907-913.
12. Saez C, Gonzalez-Baena AC, Japon MA, et al.: Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999, 40:83-88.
13. De Bellis A, Crescioli C, Grappone C, et al.: Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue. J Clin Endocrinol Metab 1998, 83:2186-2191.
14. Planz B, Aretz HT, Wang Q, et al.: Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate 1999, 41:233-242.
15. Huang YW, Wang LS, Chang HL, et al.: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol 2006, 100:24-33.
16. Giri D, Ropiquet F, Ittmann M: FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 1999, 180:53-60.
17. Cohen P, Peehl DM, Lamson G, et al.: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostatic epithelial cells. J Clin Endocrinol Metab 1991, 73:401-407.
18. Monti S, Di Silverio F, Iraci R, et al.: Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type 1 in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. J Clin Endocrinol Metab 2001, 86:1700-1706.
19. Luo J, Dunn T, Ewing C, et al.: Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002, 51:189-200.
20. Dong G, Roopmathy R, Vu T, et al.: Decreased expression of Wilm's tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1997, 82:2198-2203.
21. Grant ES, Ross MB, Ballard S, et al.: The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells. J Clin Endocrinol Metab 1998, 83:3252-3257.
22. Boudon C, Rodier G, Lechevallier E, et al.: Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 1996, 81:612-617.
23. Cohen P, Peehl DM, Baker B, et al.: Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994, 79:1410-1415.
24. Thomas LN, Wright AS, Lazier CB, et al.: Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5. Prostate 2000, 42:203-210.
25. Royuela M, De Miguel MP, Bethencourt FR, et al.: Transforming growth factor beta 1 and its receptor types I and II: comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors 1998, 16:101-110.
26. Klingler HC, Bretland AJ, Reid SV, et al.: Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFbeta). Prostate 1999, 41:110-120.
27. Mori H, Maki M, Oishi K, et al.: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 1990, 16:71-80.
28. Peehl DM, Sellers RG: Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 1997, 232:208-215.
29. Tuxhorn JA, Ayala GE, Smith MJ, et al.: Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002, 8:2912-2923.
30. Untergasser G, Gander R, Lilg C, et al.: Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev 2005, 126:59-69.
31. Fukabori Y, Nakano K, Ohyama A, et al.: Stimulative effect of transforming growth factor-beta on collagen synthesis by human prostatic stromal cells in vitro. Int J Urol 1997, 4:597-602.
32. Kakehi Y, Segawa T, Wu XX, et al.: Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 2004, 59:351-356.
33. Taoka R, Tsukuda F, Ishikawa M, et al.: Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004, 171:2330-2335.
34. Jackson MW, Bentel JM, Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997, 157:2323-2328.
35. Doll JA, Reiher FK, Crawford SE, et al.: Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49:293-305.
36. Soulitzis N, Karyotis I, Delakas D, et al.: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006, 29:305-314.
37. Nickel JC, Downey J, Young I, et al.: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999, 84:976-981.
38. Steiner G, Gessl A, Kramer G, et al.: Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994, 151:480-484.
39. Lee KL, Peehl DM: Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004, 172:1784-1791.
40. Kramer G, Steiner GE, Handisurya A, et al.: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52:43-58.
41. Konig JE, Senge T, Allhoff EP, et al.: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004, 58:121-129.
42. Giri D, Ittmann M: Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. J Pathol 2001, 159:139-147.
43. Castro P, Xia C, Gomez L, et al.: Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004, 60:153-159.
44. Penna G, Mondaini N, Amuchastegui S, et al.: Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007, 51:524-533.
45. Steiner GE, Newman ME, Paikl D, et al.: Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
46. Albini A, Tosetti F, Benelli R, et al.: Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005, 65:10637-10641.
47. Chen Y, Du XY: Functional properties and intercellular signaling of CCN1/Cyr61. J Cell Biochem 2006, Dec 14 [Epub ahead of print].
48. Sakamoto S, Yokoyama M, Zhang X, et al.: Increased expression of Cyr61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 2004, 145:2929-2940.
49. Sakamoto S, Yokoyama M, Aoki M, et al.: Induction and function of Cyr61 (CCN1) in prostatic stromal and epithelial cells: Cyr61 is required for prostatic cell proliferation. Prostate 2004, 61:305-317.
50. Prakash K, Pirozzi G, Elashoff M, et al.: Symptomatic and asymptomatic benign hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002, 99:7598-7603.